- Conditions
- Pediatric Feeding Disorder, Chronic, Avoidant Restrictive Food Intake Disorder
- Interventions
- Cyproheptadine, Nutritional Counseling, Behavioral Counseling
- Drug · Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 2 Years to 6 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2617–2640
of 12,573
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypoglycemia, Diabetes Mellitus
- Interventions
- Octreotide (drug)
- Drug
- Lead sponsor
- Albert Einstein Healthcare Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
- Interventions
- Dexamethasone, Vincristine, Inotuzumab, Blinatumomab, Dasatinib, IT MHA, Cyclophosphamide, Cytarabine, Methotrexate, 6-Mercaptopurine, Calaspargase, Daunorubicin, Thioguanine
- Drug · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 3
- States / cities
- Charlotte, North Carolina • Tulsa, Oklahoma • Memphis, Tennessee
- Conditions
- Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
- Interventions
- SY-5609, Fulvestrant, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- Syros Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Los Angeles, California • Orlando, Florida + 11 more
- Conditions
- T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma Refractory
- Interventions
- Duvelisib, Venetoclax
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Leiomyosarcoma
- Interventions
- Rucaparib, Nivolumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Lymphoma, Mantle Cell
- Interventions
- Acalabrutinib, Bendamustine, Rituximab, Placebo
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 635 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Downey, California • Santa Monica, California + 27 more
- Conditions
- Chronic Lymphocytic Leukemia, Small-Cell Lymphoma
- Interventions
- Ibrutinib, Obinutuzumab, Chlorambucil
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 8
- States / cities
- La Jolla, California • Fort Myers, Florida • West Palm Beach, Florida + 5 more
- Conditions
- Stage III Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage IVA Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma, Stage IIC Adult Soft Tissue Sarcoma
- Interventions
- doxorubicin, filgrastim, ifosfamide, biological response modifier therapy, brachytherapy, chemotherapy, colony-stimulating factor therapy, conventional surgery, cytokine therapy, intraoperative radiotherapy, radiation therapy, surgery
- Drug · Procedure
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 216
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more
- Conditions
- NSCLC, Gastric Cancer
- Interventions
- PEGPH20, Pembrolizumab
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 25 more
- Conditions
- Asthma
- Interventions
- FLOVENT™ DISKUS™ 100 mcg BID, ADVAIR™ DISKUS™ 100/50 mcg BID
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Bakersfield, California • Fresno, California + 33 more
- Conditions
- Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory, Chronic Myeloid Leukemia - Accelerated Phase, Myelodysplastic Syndromes
- Interventions
- Intensity modulated total marrow irradiation, Cyclophosphamide (CTX), Fludarabine (Fludara), Busulfan (conditioning for ALLO Transplant)
- Radiation · Drug
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Colorectal Cancer Liver Metastases (CRLM), Small Future Liver Remnant (FLR)
- Interventions
- Embolization
- Procedure
- Lead sponsor
- Maastricht University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Cholangitis, Sclerosing
- Interventions
- Oral all-trans retinoic acid (ATRA)
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Rochester, Minnesota
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer, Prostate Cancer
- Interventions
- Cabozantinib, Zanzalintinib, Atezolizumab, Nivolumab, Abiraterone, Prednisone, Enzalutamide
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Bay Shore, New York • Kettering, Ohio • Memphis, Tennessee + 1 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Osimertinib, Datopotamab Deruxtecan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 37
- States / cities
- Fountain Valley, California • Los Alamitos, California • Los Angeles, California + 32 more
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome
- Interventions
- Gemtuzumab Ozogamicin
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 1
- States / cities
- Valhalla, New York
- Conditions
- Solid Tumors
- Interventions
- Epacadostat, Nivolumab, Ipilimumab, Lirilumab
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Los Angeles, California • Santa Monica, California + 2 more
- Conditions
- Marfan Syndrome
- Interventions
- Exercise Intervention Group, Control Group
- Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Interventions
- Rituximab, Zanubrutinib
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- exemestane, adjuvant therapy, aromatase inhibition, conventional surgery, endocrine therapy, hormone therapy, neoadjuvant therapy, surgery
- Drug · Procedure
- Lead sponsor
- Robert H. Lurie Cancer Center
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced Cancer
- Interventions
- LY2090314, pemetrexed, Carboplatin, ranitidine
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Nashville, Tennessee
- Conditions
- HPV-Negative Squamous Cell Carcinoma
- Interventions
- Paclitaxel, Carboplatin, Cetuximab, Standard Dose Radiation, Low Dose Radiation, Cisplatin, TFHX Regimen
- Drug · Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- High Blood Pressure
- Interventions
- Thiazide Treatment Group, Intensified Thiazide Treatment Group, Combination Medication Treatment Group
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 35 Years to 59 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California